Tonix Pharmaceuticals Holding Corp. received approval from Nasdaq to transfer the listing of its common stock. The transfer is from The Nasdaq Capital Market to The Nasdaq Global Select Market. Trading on the Nasdaq Global Select Market is expected to commence at the open of market on March 3, 2026, under the existing ticker symbol TNXP. The uplisting reflects the company's compliance with Nasdaq Global Select Market's higher financial and corporate governance standards. The Nasdaq Global Select Market is the highest of the three Nasdaq market tiers. Tonix Pharmaceuticals is a fully integrated, commercial biotechnology company focused on central nervous system (CNS) and immunology treatments. The company's flagship medicine, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), was recently approved as the first new treatment for fibromyalgia in over 15 years. Tonix's CNS commercial infrastructure supports its marketed acute migraine products, Zembrace SymTouch and Tosymra. The company is also advancing TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder. The CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome. Tonix is advancing immunology programs, including TNX-4800 for Lyme disease prophylaxis and TNX-1500 for the prevention of kidney transplant rejection.